{"references": ["Potapov V. A. Multitarget approach to the treatment of fibrocystic mastopathy and prevention of breast cancer / Women's Health. No. 1 (107). 18-18.", "Kuligina E. Sh. Epidemiological and molecular aspects of breast cancer. Kuligina // Pract. oncology. 2010. Vol. 11, No. 4. P. 203 - 216.", "Breast cancer: a unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care (Order of the Ministry of Health of Ukraine No. 396).", "Castillo E. Effect of alpha dihydroer-gocriptine in patients with fibrocystis breast disease / E. Castillo, M. Garibay, and F. Mirabent // Gynecol. Obstet. Mex. 2006. No. 74. R. 580 - 584.", "Zulkarnaeva E.T. Indinol-3-carbinol in the treatment of benign breast diseases / E.T. Zulkarnaeva, A.D. Khakimova, EI Lapan, IL Blagodetev // Tumors of the female reproductive system. 2008. \u2116 3. P. 50 - 54.", "Brew C.T., Aronchik I., Hsu J.C. et al. Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells. Int J Cancer 2006; 118 (4): 857 - 68.", "Kukhtenko G. P. The phenomena of thixotropy and reopexia in the study of the structural-mechanical properties of soft drugs / Kuhtenko GP, Gladukh EV // Modern achievements of pharmaceutical technology and biotechnology: a collection of scientific papers, issue 3. X .: Edition of NFaU, 2017. P. 168 - 170.", "Fedorovska M. I. Development of technology of cream-mask with herbal substances for the treatment of androgenic alopecia / M.I. Fedorovska, N. P. Polovko, N. S. Leochka // ScienceRise. - 2017. - \u2116 3 (7) - P. 19-24.", "Shekhavtsova, KA Soft drugs in complex therapy of mastopathy / KA Shekhavtsova, SS Zuikina // Khabarshys. Newspaper. Vol. 1. Republican Scientific Journal No. 4 (77). 2016, pp. 19 - 21.", "Zuikina S. Research on the development of the basis of combined gel for mastopathy treatment / Svetlana Zuikina, Lilia Vyshnevska Mat. The 10th International Pharmaceutical Conference \"Science and Practice 2019\" is organized by the Lithuanian University of Health Sciences, Faculty of Pharmacy. November 15th, 2019 Kaunas, Lithuania. 2019. P. 107.", "Shchokina KG, Viktorov OP, Suprun EV, Ishchenko OM, Kovalenko EM Comparison of antiproliferative activity of modern and perspective anti-inflammatory drugs // Pharmacom. 2005. \u21164. P.104 \u2013 106.", "State Pharmacopoeia of Ukraine / State Enterprise \"Ukrainian Scientific Pharmacopoeial Center for Medicinal Products Quality\" - 1st edition. - Kharkiv: State Enterprise \"Ukrainian Scientific Pharmacopoeial Center for Medicinal Products Quality\". 2014. T. 2. 724 p."]}

According to the International Agency for Research on Cancer (IARC) at WHO, more than 1.7 million women are diagnosed with breast cancer annually. In Ukraine, according to the National Cancer Registry, in 2013, BC was first identified in 16,624 women (in 2012 – 16,660), which is 72.2 cases (in 2012 – 67) for every 100,000 women in the country. The global death toll from this disease is growing and is killing more than 500,000 women worldwide annually. According to experts from the National Cancer Institute, a diagnosis of breast cancer by the end of 2020 may become a reality for almost 17% of Ukrainian women, which gives reason to view it as a socially significant epidemiological problem. The aim of the study was to substantiate the choice of NSAIDs and their concentration for use in the development of combination gel for the treatment of mastopathy and prevention of breast cancer. The methods of literary analysis, marketing research and biopharmaceutical methods in vitro were used. The results of marketing studies and pharmacological studies of the level and types of activity of NSAIDs allowed indometacin to be selected as the active pharmaceutical ingredient (API). According to the results of biopharmaceutical studies, the concentration of the active substance in the composition of the gel is established.